Artificial Intelligence
Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors
<!– Name:DistributionId Value:8810314 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:4573 –> <!– Name:CustomerId Value:1216234 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:60f4403e-440c-45e0-9e73-2c8d6a96d7c1 –>
– Results of dose escalation portion from phase 1b/2 trials of ADG126 in combination with anti-PD-1 therapies, including confirmed clinical responses, pave way for dose expansion in specific tumors –
– Tumor shrinkage and prolonged stable disease observed in ‘cold’ tumors such as MSS CRC –
– Robust safety profile allows repeat dosing, sustained target engagement and Treg depletion to maximize long-term clinical benefit –
SAN DIEGO and SUZHOU, China, April 18, 2023 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced interim results from its combination dose escalation studies of the masked, anti-CTLA-4 SAFEbody, ADG126, presented at the AACR Annual Meeting in Orlando, Florida, April 14-19, 2023.
Two poster presentations on ADG126 SAFEbody reported results of ongoing phase 1b/2 trials at multiple dosing regimens (6 mg/kg and 10 mg/kg) in combination with either pembrolizumab or toripalimab, as well as updated data for ADG126 monotherapy in heavily pre-treated patients.
Both posters, “Interim results of a phase 1b/2 study of ADG126 (a masked anti-CTLA-4 SAFEbody®) monotherapy and in combination with toripalimab (an anti-PD-1 antibody) in patients (pts) with advanced / metastatic solid tumors” and “Initial results of a phase 1b/2 study of ADG126 (a masked anti-CTLA-4 SAFEbody®) in combination with pembrolizumab (an anti-PD-1 antibody) in patients with advanced/metastatic solid tumors,” may be viewed on the company’s website here.
Key findings include:
- Best-in-class Safety Profile Reinforced in Combination with Anti-PD-1: In dose escalation studies of ADG126 in combination with anti-PD-1 treatments, ADG126 continues to demonstrate a best-in-class safety profile at doses from 6 mg/kg up to 10 mg/kg. The combination was well tolerated with no dose-limiting toxicities observed with repeat cycles, including in patients who received four or more cycles in the combination cohort with toripalimab.
Across 31 patients in combination dose escalation cohorts of ADG126, a total of seven (22.6%) Grade 3 TRAEs were reported, suggesting a safety profile comparable to anti-PD-1 monotherapy and a best-in-class safety profile in combination with anti-PD-1, even at much higher doses. This has been achieved without aggressive safety management for immune-mediated diarrhea/colitis, such as infliximab infusion.
- Confirmed Clinical Responses & Tumor Shrinkage in Combination with Anti-PD-1: In the heavily pre-treated patient groups, clinical responses and tumor shrinkage were observed during combination dose escalation. The posters summarize patient case studies demonstrating clinical benefit, including three confirmed partial responses and multiple cases of prolonged stable disease with tumor shrinkage in patients who received ADG126 plus anti-PD-1 therapies. Of note, two cases of significant tumor shrinkage (20% reduction and higher in target lesions) were observed in MSS CRC patients with liver metastasis who received ADG126 plus toripalimab.
- Compelling Monotherapy Safety Profile with Prolonged Stable Disease Supports ADG126 Mechanism: An additional cohort of 30 patients who received ADG126 monotherapy showed a compelling safety profile for ADG126, with no Grade 3 or higher TRAEs reported at repeat doses up to 20 mg/kg.
- Across all dose levels, the disease control rate was 37% among 27 evaluable patients.
- Prolonged stable disease was observed in five patients, with notable tumor shrinkage observed in an ovarian cancer patient who received 25 cycles at 1 mg/kg and a non-small cell lung cancer patient (NSCLC) who received 14 cycles at 20 mg/kg.
- Analysis of a clinical sample from a hepatocellular carcinoma (HCC) patient previously treated with atezolizumab and bevacizumab demonstrated Treg depletion, supporting the mechanism of action for ADG126.
- Combination Dose Expansion Ongoing in MSS CRC: Dose expansion cohorts are currently underway evaluating ADG126 in combination with anti-PD-1 therapy with an update planned later in 2023. The cohorts evaluate disease control rate, progression free survival, overall survival and objective response rate. Multiple dosing schedules are being evaluated, including ADG126 10 mg/kg every three and six weeks.
Further, the strong safety profile of ADG126 has enabled a randomized clinical trial that is being initiated in collaboration with Roche to evaluate ADG126 in combination with atezolizumab and bevacizumab as a first-line treatment for patients with advanced/metastatic HCC. The trial is being sponsored and conducted by Roche.
Solid Tumor Potential Shown for ADG153, a masked, anti-CD47 IgG1 SAFEbody
A third poster, “ADG153, a novel masked anti-CD47 IgG1 SAFEbody, demonstrates strong in vivo anti-tumor activities in preclinical solid tumor models and preferential CD47 target engagement in the tumor microenvironment,” reported preclinical data for ADG153. The data demonstrated strong in vivo anti-tumor activities in solid tumor models and a robust safety profile due to preferential CD47 target engagement in the tumor microenvironment.
The three posters are available on the company’s website at www.adagene.com/pipeline/publications in accordance with the AACR embargo policy.
About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody®, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.
For more information, please visit: https://investor.adagene.com. Follow Adagene on WeChat, LinkedIn and Twitter.
SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.
Safe Harbor Statement
This press release contains forward-looking statements, including statements regarding ADG126 and ADG153, the potential implications of clinical and preclinical findings of these product candidates, and Adagene’s advancement of, and anticipated clinical development, regulatory milestones and commercialization of Adagene pipeline candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene’s drug candidates; Adagene’s ability to achieve commercial success for its drug candidates, if approved; Adagene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene’s reliance on third parties to conduct drug development, manufacturing and other services; Adagene’s limited operating history and Adagene’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene’s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene’s clinical development, commercial and other operations, as well as those risks more fully discussed in the “Risk Factors” section in Adagene’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
Artificial Intelligence
Grant Cardone Lists $42M Miami Mansion on Blockchain Real Estate Platform Propy
American best-selling author, businessman, and investor chooses Propy’s onchain real estate platform to list Golden Beach, Florida, house.
MIAMI, July 2, 2024 /PRNewswire/ — Propy, a technology company revolutionizing real estate via blockchain and AI, today announced that high-profile American entrepreneur Grant Cardone has listed a Golden Beach, Florida, private property for sale on Propy’s blockchain-based real estate platform with an asking price of $42,000,000 accepting cryptocurrency. This marks the first venture into emerging technologies in proptech for Cardone, a serial founder, best-selling author, equity fund manager, and business and real estate investor. The home is listed on the Propy marketplace with the deed minted onchain.
Propy simplifies the home-purchasing experience and eliminates fraudulent transactions by using a decentralized title registry and an escrow settlement protocol for securely storing land records and facilitating transactions, as well as accepting or converting cryptocurrency if a buyer chooses this form of payment. Leveraging the immutability of the blockchain, Propy ensures that buyer and seller private information is secure throughout the transaction. Automating and bringing the entire process online and onchain enables closing on a property to be faster, easier, and more secure than the outdated, traditional real estate transaction model.
Commenting on the listing, Grant Cardone said, “We are all in on blockchain revolutionizing real estate. We are leveraging top-tier technology to make transactions seamless and unstoppable. This is the future of real estate, and we’re leading the charge!”
The private address is minted on PropyKeys protocol – an onchain tokenized address market developed on the Base network (Coinbase Layer 2 on Ethereum). PropyKeys brings real estate onchain through NFT home addresses and aims to bring one million home addresses onchain by 2025. The Propy marketplace also grants prospective buyers the option to pay using Bitcoin or US dollars.
Natalia Karayaneva, Founder and CEO of Propy, said, “It is a privilege for us to be the platform of choice for high-end property sellers, enhancing our offering to our community of high net-worth individuals, investors, and crypto buyers. With Propy’s advanced blockchain rails, compliant crypto and dollar payments, and unwavering focus on privacy, our clients can confidently navigate the closing process. The inclusion of Cardone’s listing in BTC and USD on Propy, minted with our latest privacy deed feature, highlights our leadership in the intersection of real estate and crypto.”
Additional details on the Cardone property are available on Propy’s website. Interested parties should contact the listing agent for viewings and further details.
Natalia Karayaneva, Founder and CEO of Propy, is available for interview upon request.
About Propy:
Propy is a US-licensed title company and a pioneering platform leveraging blockchain and AI technology to facilitate seamless transactions of real-world assets (RWA), specifically focused on revolutionizing global real estate markets. As an industry leader, Propy specializes in providing secure and efficient solutions, ensuring an enhanced experience for buying and selling properties worldwide.
Website | Facebook | X
Photo: https://mma.prnewswire.com/media/2452961/Grant_Cardone_mansion.jpg
View original content:https://www.prnewswire.co.uk/news-releases/grant-cardone-lists-42m-miami-mansion-on-blockchain-real-estate-platform-propy-302188274.html
Artificial Intelligence
DataLend: Securities Lending Revenue Down 16% Year-Over-Year to $2.53 Billion in Q2 2024
Global revenue declines year-over-year due to lagging equities performance in the U.S. and EMEA
NEW YORK, July 2, 2024 /PRNewswire/ — The global securities finance industry generated $2.53 billion in revenue for lenders in the second quarter of 2024, according to DataLend, the market data service of fintech EquiLend. The figure represents a 16% decrease from the $3.00 billion generated in Q2 2023.
Global broker-to-broker activity, where broker-dealers lend and borrow securities from each other, generated an additional $696 million in revenue during Q2, a 9% decrease year-over-year.
Regionally, equity revenue fell 33% in EMEA and 19% in North America compared to the same period last year. A 22% decline in fees in North America and a 23% dip in EMEA accounted for the majority of the decreased revenue. Equity revenue in APAC increased 8% thanks to a 13% increase in fees.
Global fixed income performance declined by 11% in Q2 year-over-year. While revenue from government securities was roughly flat, corporate debt revenue fell by 32%, a regression of a trend which saw corporate bonds running hot through much of 2022 and 2023.
In June 2024, the global securities finance industry generated $790 million in revenue for lenders. The figure represents a 11% decrease year-over-year from the $888 million generated in June 2023. Broker-to-broker activity totaled an additional $207 million in revenue in June, also an 11% decrease year-over-year.
The top five earners in June 2024 were Lucid Group (LCID US), Trump Media & Technology Group (DJT US), Canopy Growth Corporation NPV (CGC US & WEED CN), Beyond Meat Inc. (BYND US) and ImmunityBio Inc. (IBRX US). In total, the group generated $56 million in revenue in the month.
Bloomberg Terminal users can subscribe to EquiLend’s exclusive Orbisa securities lending data by entering terminal shortcut APPS ORBISA or clicking the following link: https://blinks.bloomberg.com/screens/apps%20orbisa.
About DataLend
DataLend, the market data service within EquiLend’s Data & Analytics Solutions group, tracks daily market movements across more than 200,000 securities, covering $35 trillion in lendable assets and $2.6 trillion in on-loan assets for the securities finance market. www.datalend.com
About EquiLend
EquiLend is a global financial technology firm offering Trading, Post-Trade, Data & Analytics, RegTech and Platform Solutions for the securities finance industry. With offices in North America, EMEA and Asia-Pacific, EquiLend operates across various jurisdictions worldwide, adhering to the highest regulatory standards. The company is committed to excellence and innovation and is consistently recognized for its contributions to the industry. EquiLend is Great Place to Work Certified™ in the U.S., UK, Ireland and India and has been honored as the Best Post-Trade Service Provider Globally, Best Market Data Provider Globally and for its outstanding Diversity & Inclusion initiatives in the Securities Finance Times Industry Excellence Awards 2023. www.equilend.com
Logo – https://mma.prnewswire.com/media/1060364/EquiLend_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/datalend-securities-lending-revenue-down-16-year-over-year-to-2-53-billion-in-q2-2024–302188137.html
Artificial Intelligence
Endpoint Security Market to Transcend USD 36.01 billion by 2031 Owing to Cutting-Edge Cybersecurity in Safeguarding Online Infrastructure| SkyQuest Technology
WESTFORD, Mass., July 2, 2024 /PRNewswire/ — According to SkyQuest, the global Endpoint Security Market size was valued at USD 10.40 billion in 2022 and is poised to grow from USD 11.94 billion in 2023 to USD 36.01 billion by 2031, growing at a CAGR of 14.8% in the forecast period (2024-2031).
Organizations use advanced security solutions as their first line of defense in cybersecurity to protect their company network infrastructure. Market expansion is anticipated as Bring Your Own Device (BYOD) policies are implemented more frequently. For instance, the web threat intelligence detection XDR solution FortiXDR was introduced by Fortinet, Inc. BlackBerry Limited introduced the managed detection and response (MDR) service in a similar manner. Additionally, for endpoint security, Broadcom, Inc. has introduced Adaptive Protection. Solutions are heavily reliant on emerging technology, including cloud computing, artificial intelligence (AI), the Internet of Things (IoT), and others.
Download a detailed overview:
https://www.skyquestt.com/sample-request/endpoint-security-market
Endpoint Security Market Overview:
Report Coverage
Details
Market Revenue in 2023
$ 11.94 billion
Estimated Value by 2031
$ 36.01 billion
Growth Rate
Poised to grow at a CAGR of 14.8%
Forecast Period
2024–2031
Forecast Units
Value (USD Billion)
Report Coverage
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered
Component, Enforcement Point, Enterprise Size, End-User and Deployment
Geographies Covered
North America, Europe, Asia Pacific, Middle East & Africa, Latin America
Report Highlights
Updated financial information / product portfolio of players
Key Market Opportunities
Rising Number of Connected Devices
Key Market Drivers
Rising trend of BYOD
Segments covered in Endpoint Security Market are as follows:
ComponentSolutions (Endpoint Protection Platform (EPP) (Antivirus, Anti-Spyware/Anti-Malware, Firewall, Endpoint Device Control, Intrusion Prevention, Endpoint Application Control, Others), Endpoint Detection and Response (EDR)), Services (Professional Services (Training and Consulting, Integration and Implementation, Support and Maintenance), Managed Services)Enforcement PointWorkstations, Mobile Devices, Servers, Point of Sale Terminals, OthersEnterprise SizeLarge Enterprises, Small and Medium Enterprises (SMEs)End-UserGovernment & Public Sector, BFSI, Healthcare, IT & Telecom, Transportation, Education, Manufacturing, Retail & e-commerce, OthersDeploymentCloud, and On-PremiseRequest Free Customization of this report:
https://www.skyquestt.com/speak-with-analyst/endpoint-security-market
Large Enterprises Redefining Endpoint Security in Global Arena
The worldwide endpoint security market is shaped in large part by the size of the enterprise. The need for comprehensive and scalable solutions is generally driven by large organisations, whilst small and medium-sized enterprises (SMEs) prioritise cost-effective security measures that are suited to their specific needs. Market strategies and product development are influenced by this segmentation to effectively meet the diverse needs and budgets of organisations.
Large corporations have a great deal of influence in the global endpoint security market, owing to their sizable financial backing for all-encompassing cybersecurity solutions. By fitting by the artificial intelligence and machine learning technology as well as having the wide network infrastructure and following to regulation guidelines strictly, they hold an exclusive position to enhance ingenuity and expand market and at the same time set up security standards in the industry.
SMEs being small and financially limited create a big part of the world’s endpoint security demand driving demand for trustworthy, low-priced security solutions. Small and financially constrained firms need help protecting themselves from cyber threats as they tend to adopt new tech fast, yet they face higher risks of online attacks. This is due to SMEs are quick in adopting new technologies but are also at risk from online attacks.
View report summary and Table of Contents (TOC):
https://www.skyquestt.com/report/endpoint-security-market
Optimizing Performance through Strategic Deployment in Endpoint Security
Deployment in the worldwide endpoint security sector signifies the activities involving placing security systems into operation and orchestrating these solutions across various networks and gadgets. It is proverbial that deploying well means better protection from cyber-attacks, fewer weak points, more speed thereby preserving invaluable information for all organizations worldwide.
In the worldwide endpoint security industry, on-premises deployment gives users more control and customisation by installing security solutions directly on local servers and devices. This method is critical for companies with strict regulations on data security since it ensures that they adhere to legal requirements, directly control their sensitive information thereby upholding strong security and operational integrity.
In the worldwide endpoint security industry, cloud deployment uses remote servers to offer flexible, scalable security solutions. This approach is central in enabling organization to promptly respond to fresh dangers, reduce infrastructure budget and maintain reliable real time security on all endpoints as it is easy to incorporate, affordable and allows immediate updates.
Crucial Role of Enterprise Size and Advanced Deployment Strategies To turn Fruitful
Modern advanced security solutions are essential for safeguarding organisational network infrastructures in the quickly changing digital landscape of today. The increased spread of BYOD policies is driving demand for such cutting-edge solutions as Broadcom’s Adaptive Protection, BlackBerry’s MDR, and Fortinet’s FortiXDR. Advanced technology adoption, compliance, and scalability are key priorities for big enterprises, which use their large resource bases, while small and midsize businesses are pushing for good quality and affordable cybersecurity solutions. Efficient implementation, regardless of on-premises or cloud-based options, guarantees all-encompassing security and uninterrupted operations, providing defence against the continuously increasing risk of cyberattacks.
Related Reports:
Cyber Security Market
Network Security Market
Managed Security Services Market
Cloud Security Market
Application Security Market
About Us:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization has expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact:Mr. Jagraj SinghSkyQuest Technology1 Apache Way,Westford,Massachusetts 01886USA (+1) 351-333-4748Email: [email protected] Our Website: https://www.skyquestt.com/
Logo : https://mma.prnewswire.com/media/2446095/SkyQuest_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/endpoint-security-market-to-transcend-usd-36-01-billion-by-2031-owing-to-cutting-edge-cybersecurity-in-safeguarding-online-infrastructure-skyquest-technology-302187917.html
-
Artificial Intelligence4 days ago
CO2 AI Launches First Solution to Compute Product Emissions at Scale
-
Artificial Intelligence4 days agoSpotlight on Authentic AI: Developers Making Real Contributions Beyond AI Washing Claims
-
Artificial Intelligence4 days agoAsia Pacific View: Foreigners Looking for the Most Practical Smart Technology at the 2024 World Intelligence Expo
-
Artificial Intelligence4 days agoLucinity’s AI Innovation Recognized at Microsoft’s Prestigious Global Partner Awards 2024
-
Artificial Intelligence4 days ago
Learning Pool Recognized with Two Industry Awards for Innovation and Product Excellence
-
Artificial Intelligence4 days ago
Tech Companies Leading the Charge in the Transformative AI Era
-
Artificial Intelligence4 days agoHybrid Memory Cube Market Size to Grow USD 18651.2 Million by 2030 at a CAGR of 18.6% | Valuates Reports
-
Artificial Intelligence4 days ago
North American grocery retailer digitizes stores with Pricer Plaza in 90 MSEK order
